Trial Profile
Ruxolitinib and Methylprednisolone as First Line Therapy for Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Methylprednisolone (Primary) ; Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 15 Oct 2018 New trial record
- 12 Oct 2018 Planned End Date changed from 30 Sep 2021 to 31 Oct 2021.
- 12 Oct 2018 Planned primary completion date changed from 30 Sep 2021 to 31 Oct 2021.